Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Approximately 185 million people are infected with chronic hepatitis C (HCV) infection worldwide, and about 5 million are co-infected with human immunodeficiency virus (HIV).1 In the United States, co-infection occurs in approximately one-third of all patients with HIV-1 infection, with incidence rates as high as 75% to 90% among patients with reported history of intravenous drug use, and is associated with higher rates of end-stage liver disease, liver cancer, and mortality.2,3